

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1783 Session of 2023

INTRODUCED BY VENKAT, MADDEN, MARCELL, KINSEY, PROBST, KHAN, FREEMAN, NEILSON, HILL-EVANS, SCHLOSSBERG, DELLOSO, SANCHEZ, HOWARD, D. WILLIAMS, STEELE, KAZEEM, JOZWIAK, CEPEDA-FREYTIZ, BOROWSKI, PASHINSKI, HOHENSTEIN, ABNEY, A. BROWN, FLICK, GIRAL, SHUSTERMAN, HANBIDGE, POWELL, DALEY, CERRATO AND GREEN, OCTOBER 24, 2023

AS REPORTED FROM COMMITTEE ON HUMAN SERVICES, HOUSE OF REPRESENTATIVES, AS AMENDED, APRIL 29, 2024

AN ACT

1 Amending the act of April 14, 1972 (P.L.233, No.64), entitled
2 "An act relating to the manufacture, sale and possession of
3 controlled substances, other drugs, devices and cosmetics;
4 conferring powers on the courts and the secretary and
5 Department of Health, and a newly created Pennsylvania Drug,
6 Device and Cosmetic Board; establishing schedules of
7 controlled substances; providing penalties; requiring
8 registration of persons engaged in the drug trade and for the
9 revocation or suspension of certain licenses and
10 registrations; and repealing an act," further providing for
11 drug overdose medication.

12 The General Assembly of the Commonwealth of Pennsylvania
13 hereby enacts as follows:

14 Section 1. Section 13.8(a)(3) and (h) of the act of April
15 14, 1972 (P.L.233, No.64), known as The Controlled Substance,
16 Drug, Device and Cosmetic Act, amended November 3, 2022
17 (P.L.1984, No.135), are amended and the section is amended by
18 adding a ~~subsection~~ SUBSECTIONS to read: <--

19 Section 13.8. Drug Overdose Medication.--(a) The
20 department, in carrying out its duties under 28 Pa. Code Ch.

1 1023 (relating to personnel), shall have the following duties:

2 \* \* \*

3 (3) The following apply:

4 (i) In consultation with the Department of Drug and Alcohol  
5 Programs, develop or approve training and instructional  
6 materials about recognizing opioid-related overdoses,  
7 administering an opioid antagonist and promptly seeking medical  
8 attention. The training and instruction materials shall be  
9 provided free of charge on the Internet.

10 (ii) In consultation with the Department of Drug and Alcohol  
11 Programs, develop a poster that contains the following  
12 information:

13 (A) The signs of an opioid-related overdose.

14 (B) What to do in the event of an opioid-related overdose.

15 (C) Where to find an opioid antagonist such as naloxone.

16 (D) Where to find additional resources and information,  
17 which may include a quick-response (QR) code or a website URL.

18 (iii) Develop a pamphlet with information equivalent to the  
19 information contained on the poster described in subparagraph  
20 (ii).

21 (iv) Make the poster described in subparagraph (ii) and the  
22 pamphlet described in subparagraph (iii) available on the  
23 publicly accessible Internet website of the department.

24 (V) PROVIDE THE POSTER DESCRIBED IN SUBPARAGRAPH (II) IN <--  
25 ADDITIONAL LANGUAGES UPON REQUEST BY AN ENTITY LISTED UNDER  
26 SUBSECTION (A.1).

27 (a.1) The following entities shall display the poster  
28 described in subsection (a) (3) (ii) IN A CONSPICUOUS LOCATION at <--  
29 each of their properties in conspicuous locations, IF PERMITTED: <--

30 (1) A Commonwealth agency.

1 (2) A metropolitan transportation authority.

2 ~~(3) A municipal authority.~~ <--

3 ~~(4) (3) A municipality.~~ <--

4 (A.2) THE DEPARTMENT SHALL PAY FOR THE COSTS ASSOCIATED WITH <--

5 PRINTING AND DISTRIBUTING EACH POSTER DESCRIBED IN SUBSECTION

6 (A) (3) (II).

7 \* \* \*

8 (h) [As used in this section, the term "opioid antagonist"

9 means a drug or device approved by the Federal Food, Drug, and

10 Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.) for

11 emergency reversal of known or suspected opioid overdose,

12 including naloxone hydrochloride or other similarly acting drugs

13 approved by the United States Food and Drug Administration for

14 the treatment of an opioid overdose.] As used in this section,

15 the following words and phrases shall have the meanings given to

16 them in this subsection unless the context clearly indicates

17 otherwise:

18 "Commonwealth agency." An executive agency or independent

19 agency as those terms are defined in 2 Pa.C.S. § 101 (relating

20 to definitions).

21 "Conspicuous location." A location where individuals are

22 likely to see and read the poster described in subsection (a) (3)

23 (ii). The term includes a bathroom, bulletin board, entrance,

24 exit, hallway or lobby.

25 "Metropolitan transportation authority." An authority

26 operating under 74 Pa.C.S. Ch. 17 (relating to metropolitan

27 transportation authorities).

28 ~~"Municipal authority." An authority created under 53 Pa.C.S.~~ <--

29 ~~Ch. 56 (relating to municipal authorities).~~

30 "Municipality." A county, city, borough, incorporated town

1 or township.

2 "Opioid antagonist." A drug or device approved by the  
3 Federal Food, Drug, and Cosmetic Act (52 Stat. 1040, 21 U.S.C. §  
4 301 et seq.) for emergency reversal of known or suspected opioid  
5 overdose, including naloxone hydrochloride or other similarly  
6 acting drugs approved by the United States Food and Drug  
7 Administration for the treatment of an opioid overdose.

8 "Property." Real property under control of an entity listed  
9 in subsection (a.1). The term includes an airport, bus stop,  
10 library, park, school or rail stop.

11 Section 2. This act shall take effect in 60 days.